Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-935 in Healthy Subjects
NCT02539134Phase 1Completed
- Sponsor
- Takeda
- Start
- Sep 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of soticlestat in epilepsy (7 cohorts), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event, Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose and 2 more. Started Sep 2015; status: completed.
02
Drugs
soticlestat
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02539134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02539134.